Company intelligence / Profile preview
Avi-Mex
- Ownership
- Private
- Development stage
- Commercial
Overview
Avi-Mex has developed a recombinant NDV-vectored COVID‑19 vaccine ("Patria") that reached Phase 3 clinical trials and showed effectiveness as a booster. The program is supported by Mexican government funding and collaboration with CastleVax for the underlying technology. Manufacturing scale-up was planned pending regulatory approval from Cofepris and potential international recognition by WHO.
- Therapeutic areas
- Infectious Diseases
- Modalities
- VaccineRecombinant proteinGenetically engineered subunit vaccineProphylactic vaccine
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Avi-Mex.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Avi-Mex.